Your browser doesn't support javascript.
loading
Enhancing Studies of Pharmacodynamic Mechanisms via Measurements of Metabolic Flux: Fundamental Concepts and Guiding Principles for Using Stable Isotope Tracers.
Daurio, Natalie A; Wang, Sheng-Ping; Chen, Ying; Zhou, Haihong; McLaren, David G; Roddy, Thomas P; Johns, Douglas G; Milot, Denise; Kasumov, Takhar; Erion, Mark D; Kelley, David E; Previs, Stephen F.
Affiliation
  • Daurio NA; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Wang SP; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Chen Y; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Zhou H; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • McLaren DG; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Roddy TP; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Johns DG; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Milot D; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Kasumov T; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Erion MD; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Kelley DE; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.).
  • Previs SF; Merck & Company, Inc., Kenilworth, New Jersey (N.A.D., S.P.W., Y.C., H.Z., D.G.M., T.P.R., D.G.J., D.M.E., D.E.K., S.P.F.), and Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, Ohio (T.K.) stephen_previs@merck.com.
J Pharmacol Exp Ther ; 363(1): 80-91, 2017 10.
Article in En | MEDLINE | ID: mdl-28724692
Drug discovery and development efforts are largely based around a common expectation, namely, that direct or indirect action on a cellular process (e.g., statin-mediated enzyme inhibition or insulin-stimulated receptor activation) will have a beneficial impact on physiologic homeostasis. To expand on this, one could argue that virtually all pharmacologic interventions attempt to influence the flow of "traffic" in a biochemical network, irrespective of disease or modality. Since stable isotope tracer kinetic methods provide a measure of traffic flow (i.e., metabolic flux), their inclusion in study designs can yield novel information regarding pathway biology; the application of such methods requires the integration of knowledge in physiology, analytical chemistry, and mathematical modeling. Herein, we review the fundamental concepts that surround the use of tracer kinetics, define basic terms, and outline guiding principles via theoretical and experimental problems. Specifically, one needs to 1) recognize the types of biochemical events that change isotopic enrichments, 2) appreciate the distinction between fractional turnover and flux rate, and 3) be aware of the subtle differences between tracer kinetics and pharmacokinetics. We hope investigators can use the framework presented here to develop applications that address their specific questions surrounding biochemical flux, and thereby gain insight into the pathophysiology of disease states, and examine pharmacodynamic mechanisms.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Discovery / Metabolic Flux Analysis Limits: Animals / Humans Language: En Journal: J Pharmacol Exp Ther Year: 2017 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Drug Discovery / Metabolic Flux Analysis Limits: Animals / Humans Language: En Journal: J Pharmacol Exp Ther Year: 2017 Document type: Article Country of publication: United States